Development and Evaluation of Trazodone Hydrochloride Tablets for Oral Drug Delivery Technology

Abstract

Usually, conventional oral drugs such as tablets and capsules are formulated to rapidly release the active ingredient into the body when ingested orally. This facilitates speedy and complete assimilation of the medication into the circulatory system, resulting in a prompt onset of its effects. The term “modified release drug product” pertains to drugs that alter the timing and/or rate of drug component release. The objective of study was to develop and evaluate a matrix tablet that achieves prolonged release of trazodone hydrochloride. Trazodone hydrochloride is an orally administered novel antidepressant medication. Mood disorders, phobias, and social anxiety disorders are common indications for its usage. Two different forms of trazodone hydrochloride medications are now on the market: Rapid-release tablets and prolonged-release capsules. Effexor and Effexor XR are the brand names under which these drugs are marketed. Trazodone hydrochloride has a short biological half-life of 5 hours, which means that it is necessary to take 2 to 3 dosages each day. The optimal daily dose falls within the range of 75 to 450 mg/day. Trazodone hydrochloride is a kind of medicine used for long-term treatment of depression. Thus, to decrease the occurrence of dosing, we chose to develop straightforward and cost-effective sustained-release tablets of trazodone.